Goldman Sachs Reiterates Neutral on United Therapeutics Corporation

Goldman Sachs reiterated its Neutral rating on United Therapeutics Corporation

. United Therapeutics is expected to announce the Phase 3 data for its new drug Remodulin. Goldman feels the results will be better than other analysts predict. In a research report published today, Goldman states, "We continue to be more optimistic than the market that oral Remo will succeed and we assign a 75% probability of success based on: (1) Remo targets a relevant pathway for PAH. (2) The initial Ph3 oral Remo trial (FREEDOM-C, released in 2008) demonstrated the drug has activity based on a subset of patients, but did not meet the primary endpoint (thought to be due to an inability to titrate). (3) The new titration schedule of oral Remo appears to be having a positive impact on tolerability in the two ongoing Ph3 trials. (4) The monotherapy design of the first Ph3 trial represents a low hurdle." On Thursday, United Therapeutics lost 0.74% to close the day at $63.11.